• Johnson & Johnson pays $300m to develop cusatuzumab pharmatimes
    December 06, 2018
    Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.
PharmaSources Customer Service